StockData
Moderna, Inc. logo

Moderna, Inc. (MRNA) stock

MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30537% above fair value
$206.80−8.47 (-3.93%)

Close on Nov 17, 2026Market cap $82.56BP/E –Yield –

Moderna gross margin

Gross margin is gross profit as a percentage of revenue.

Moderna's gross margin for the twelve months ending Jun 30, 2026 was 23.4%. For fiscal 2025 it was 55.3%, against 54.8% the year before. The highest annual figure on record is 100.0% in fiscal 2018.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202555.3%+0.6
FY2024Dec 31, 202454.8%+23.3
FY2023Dec 31, 202331.5%−40.4
FY2022Dec 31, 202271.9%−13.9
FY2021Dec 31, 202185.8%−13.2
FY2020Dec 31, 202099.0%−1.0
FY2019Dec 31, 2019100.0%+0.0
FY2018Dec 31, 2018100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202635.9%+19.7
Q1 FY2026Mar 31, 2026-145.5%−162.2
Q4 FY2025Dec 31, 202533.3%+9.8
Q3 FY2025Sep 30, 202579.6%+7.2
Q2 FY2025Jun 30, 202516.2%−36.1
Q1 FY2025Mar 31, 202516.7%−25.8
Q4 FY2024Dec 31, 202423.5%−43.5
Q3 FY2024Sep 30, 202472.4%+94.8
Q2 FY2024Jun 30, 202452.3%+164.8
Q1 FY2024Mar 31, 202442.5%−15.0
Q4 FY2023Dec 31, 202367.0%+4.7
Q3 FY2023Sep 30, 2023-22.4%−89.7
Q2 FY2023Jun 30, 2023-112.5%−183.4
Q1 FY2023Mar 31, 202357.5%−25.8
Q4 FY2022Dec 31, 202262.3%−24.5
Q3 FY2022Sep 30, 202267.3%−18.2
Q2 FY2022Jun 30, 202270.9%−11.9
Q1 FY2022Mar 31, 202283.2%−6.8
Q4 FY2021Dec 31, 202186.8%−11.8
Q3 FY2021Sep 30, 202185.5%−14.5
Q2 FY2021Jun 30, 202182.8%−17.2
Q1 FY2021Mar 31, 202190.0%−10.0
Q4 FY2020Dec 31, 202098.6%–
Q3 FY2020Sep 30, 2020100.0%–
Q2 FY2020Jun 30, 2020100.0%–
Q1 FY2020Mar 31, 2020100.0%–

More Moderna figures

See a number that looks wrong?